Vivre's performance and recovery protocols support the growth-hormone axis, tissue regeneration, and metabolic flexibility. Every compound is lot-tested; IGF-1, inflammatory markers and a metabolic panel are the markers worth tracking. WADA Prohibited status is disclosed openly for patients in regulated sport.
WADA Prohibited Substances Disclosure
Several compounds in the performance category - including BPC-157 (S0, since 2022), TB-500 (S2), MOTS-c (S2, since 2024), GHRP-2 and GHRP-6 (S2) - are on the World Anti-Doping Agency Prohibited List. If you compete in regulated sport (Olympic-pathway, professional, university), these compounds may result in a sanction.
Vivre's compound pages show the WADA status of every compound. Check the WADA status of every compound before you compete.
The Vivre Approach
Lot-tested performance compounds. Biomarker-anchored. Not bodybuilding-forum stack design.
Hormone and metabolic baseline first
IGF-1, total/free testosterone, SHBG, thyroid panel, inflammatory markers, lipid panel, fasting insulin. We don't supplement what we haven't measured.
Evidence-led, not hype-led
Forum-shared stacks have known patient-harm cases. Protocols are designed based on the audit results and adjust based on follow-up biomarkers - not based on what you read about online.
Monitoring beyond intake
IGF-1 and metabolic panel re-testing at protocol checkpoints. Sustained elevation patterns are a signal to stop and review.
Relevant ProtocolsLot-tested stacks
Performance and recovery protocols below. Your baseline helps show which is relevant - and whether any is. For some people (particularly those with elevated IGF-1 at baseline, or family history of certain cancers), no GH-axis stack is appropriate.
The Peptides in These Protocols
Individual compounds
Patients searching by compound name (CJC-1295, Ipamorelin, BPC-157) often arrive here first. Here are the individual compounds in Vivre's performance and recovery protocols, grouped by what they do. Click any compound for its detailed clinical page, including evidence base, half-life, mechanism, and WADA status.
· when body composition is part of the performance goal
Note: individual compound pages exist for education and reference. Vivre's V-Series stacks package these compounds; individual compound pages exist for education and reference.
How It Works
01
Biological Audit
Performance-focused audit - IGF-1, hormone panel, metabolic markers, inflammatory markers, lipid panel. Identifies baseline status and contraindications before any protocol discussion.
02
Read the Evidence
Review WADA implications and your baseline before choosing anything. Some audits result in "protocol not indicated"
03
Lot-tested Supply
Protocol begins with verified compound supply. IGF-1 and metabolic re-testing at checkpoints. Sustained off-range biomarkers are a signal to stop, not to self-titrate.
What Makes This Different
The untested peptide market is substantial and the harm patterns are documented. The distinguishing features of a clinically-credible programme:
Compound verification. Vivre's Double-Gate Protocol verifies every batch. Forum-sourced or research-chemical-grade compounds have no quality guarantee.
IGF-1 monitoring. The GH-axis is potent and IGF-1 elevation is the relevant safety marker. Regular IGF-1 testing is worth building in; untested use almost never includes it.
Honest contraindication framing. GH-axis protocols are declinedls for patients with elevated baseline IGF-1, certain cancer histories, or specific risk profiles. This is real clinical judgment, not gatekeeping for show.
WADA disclosure. Athletes in regulated sport are informed explicitly. Check WADA status before competing in tested categories.
Evidence Base · Perform & Recover Compounds
Primary sources · peer-reviewed
Performance and recovery peptides span a wide evidence range - from FDA-approved compounds with full Phase 3 trial data to mechanistically-validated preclinical assets. Vivre cites each at the actual level of evidence that exists.
Tier indicators (gold = human RCT, biochemistry, or genomic; amber = preclinical or investigational) reflect translational distance. Vivre presents human data prominently and flags preclinical evidence explicitly so you can weigh it honestly. Click any card for full study breakdown on the compound page.
Common Questions
Are these compounds WADA-prohibited?
Several are - including BPC-157 (S0, since 2022), TB-500 (S2), MOTS-c (S2, since 2024), GHRP-2 and GHRP-6 (S2), AICAR (S4). If you compete in WADA-regulated sport, these protocols may result in sanctions. Check your competitive status before ordering. Check WADA status before competing in tested categories.
How is this different from TRT?
TRT (testosterone replacement therapy) addresses testosterone deficiency in patients with confirmed clinical hypogonadism. Vivre's GH-axis protocols (V-G1) address the growth-hormone cascade - a different physiological system. Some patients benefit from both; others from one and not the other; some from neither. Your baseline helps show which, if any, applies. Vivre does not provide TRT - that is a conversation with your own doctor.
Will my IGF-1 go up too much?
IGF-1 elevation is the relevant safety endpoint for GH-axis protocols. Vivre monitors IGF-1 at baseline, mid-protocol, and end-of-cycle. Sustained elevation above the age-adjusted reference range is a signal to stop and review. This is why tracking matters.
What if I'm a competing athlete?
Check before you order. Check your competitive category, the testing regimen you're subject to, and the specific compound implications. If a compound is incompatible with your competitive status, do not use it.
How does this compare to peptides I see on bodybuilding forums?
Forum-sourced peptides have no verification of compound identity, purity, or dose accuracy. The harm patterns from untested use are documented in case reports. Vivre tests every lot, publishes the report and lists the markers worth tracking. Different category of product entirely.
How long until I see body composition changes?
Trajectory depends on the protocol, baseline status, training and nutrition adherence, and individual response. For GH-axis protocols, biomarker changes (IGF-1, lipid markers) are typically observable at the first re-testing checkpoint. Body composition changes typically require 12-16 weeks for measurable shift, and the rate varies substantially.
Next Step
Start with the Biological Audit.
The audit provides the data foundation. From there, check your competitive status and baseline biomarkers before choosing anything.